A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
- 1 June 2013
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 49 (9) , 2077-2085
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary CancerClinical Cancer Research, 2013
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialThe Lancet Oncology, 2012
- A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal AdenocarcinomaCancer Discovery, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway InhibitionClinical Cancer Research, 2011
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of CancerCancer Research, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genesVirchows Archiv, 2006
- Clinical features and correlates of gemcitabine‐associated lung injuryCancer, 2006
- Pharmacologic Inhibition of RAF→MEK→ERK Signaling Elicits Pancreatic Cancer Cell Cycle Arrest Through Induced Expression of p27Kip1Cancer Research, 2005